NM 3
Alternative Names: NM-3Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Mercian
- Developer Genzyme Oncology; Mercian
- Class Antineoplastics; Antirheumatics; Coumarins; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis; Solid tumours
Most Recent Events
- 29 Dec 2004 ILEX Oncology has been acquired by Genzyme Corporation
- 19 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the pharmacokinetics section
- 04 Jul 2003 No development reported - Preclinical for Rheumatoid arthritis in Japan (unspecified route)